Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $7 price target The company’s lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates since the payload is an immune-stimulatory agent instead of a cytotoxic warhead, the analyst tells investors in a research note. The firm says initial clinical results for BDC-4182 are expected in Q3 of 2026.